In India, it is the market leader in dermatology and improving its presence in respiratory, CVS, anti-infectives and anti-diabetics, in particular. It has also forayed into consumer health segment focusing on Rx-OTC switch products (~| 150 crore) led by two brands, Candid and Scalpe+ Progress on the margins front amid cost rationalisation measures and decline in R&D expenses as percentage of sales...